UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells

Sanam Sane, Andre Hafner, Rekha Srinivasan, Daniall Masood, John L. Slunecka, Collin J. Noldner, Alex D. Hanson, Taylor Kruisselbrink, Xuejun Wang, Yiyang Wang, Jun Yin, Khosrow Rezvani

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Overexpression of oncoproteins is a major cause of treatment failure using current chemotherapeutic drugs. Drug-induced degradation of oncoproteins is feasible and can improve clinical outcomes in diverse types of cancers. Mortalin-2 (mot-2) is a dominant oncoprotein in several tumors, including colorectal cancer (CRC). In addition to inactivating the p53 tumor suppressor protein, mot-2 enhances tumor cell invasion and migration. Thus, mot-2 is considered a potential therapeutic target in several cancer types. The current study investigated the biological role of a ubiquitin-like protein called UBXN2A in the regulation of mot-2 turnover. An orthogonal ubiquitin transfer technology followed by immunoprecipitation, in vitro ubiquitination, and Magnetic Beads TUBE2 pull-down experiments revealed that UBXN2A promotes carboxyl terminus of the HSP70-interacting protein (CHIP)-dependent ubiquitination of mot-2. We subsequently showed that UBXN2A increases proteasomal degradation of mot-2. A subcellular compartmentalization experiment revealed that induced UBXN2A decreases the level of mot-2 and its chaperone partner, HSP60. Pharmacological upregulation of UBXN2A using a small molecule, veratridine (VTD), decreases the level of mot-2 in cancer cells. Consistent with the in vitro results, UBXN2A+/− mice exhibited selective elevation of mot-2 in colon tissues. An in vitro Anti-K48 TUBE isolation approach showed that recombinant UBXN2A enhances proteasomal degradation of mot-2 in mouse colon tissues. Finally, we observed enhanced association of CHIP with the UBXN2A-mot-2 complex in tumors in an azoxymethane/dextran sulfate sodium-induced mouse CRC model. The existence of a multiprotein complex containing UBXN2A, CHIP, and mot-2 suggests a synergistic tumor suppressor activity of UBXN2A and CHIP in mot-2-enriched tumors. This finding validates the UBXN2A-CHIP axis as a novel and potential therapeutic target in CRC.

Original languageEnglish (US)
Pages (from-to)1753-1777
Number of pages25
JournalMolecular Oncology
Volume12
Issue number10
DOIs
StatePublished - Oct 2018

Fingerprint

Oncogene Proteins
Neoplasms
Proteins
Colorectal Neoplasms
Ubiquitination
mortalin
Colon
Ubiquitins
Azoxymethane
Veratridine
Technology Transfer
Tumor Suppressor Protein p53
Multiprotein Complexes
Dextran Sulfate
Ubiquitin
Treatment Failure
Immunoprecipitation
Pharmaceutical Preparations
Cell Movement
Up-Regulation

Keywords

  • CHIP E3 ligase
  • UBXN2A
  • colorectal cancer
  • mortalin-2
  • mouse
  • veratridine

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Cite this

Sane, S., Hafner, A., Srinivasan, R., Masood, D., Slunecka, J. L., Noldner, C. J., ... Rezvani, K. (2018). UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells. Molecular Oncology, 12(10), 1753-1777. https://doi.org/10.1002/1878-0261.12372

UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells. / Sane, Sanam; Hafner, Andre; Srinivasan, Rekha; Masood, Daniall; Slunecka, John L.; Noldner, Collin J.; Hanson, Alex D.; Kruisselbrink, Taylor; Wang, Xuejun; Wang, Yiyang; Yin, Jun; Rezvani, Khosrow.

In: Molecular Oncology, Vol. 12, No. 10, 10.2018, p. 1753-1777.

Research output: Contribution to journalArticle

Sane, S, Hafner, A, Srinivasan, R, Masood, D, Slunecka, JL, Noldner, CJ, Hanson, AD, Kruisselbrink, T, Wang, X, Wang, Y, Yin, J & Rezvani, K 2018, 'UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells', Molecular Oncology, vol. 12, no. 10, pp. 1753-1777. https://doi.org/10.1002/1878-0261.12372
Sane S, Hafner A, Srinivasan R, Masood D, Slunecka JL, Noldner CJ et al. UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells. Molecular Oncology. 2018 Oct;12(10):1753-1777. https://doi.org/10.1002/1878-0261.12372
Sane, Sanam ; Hafner, Andre ; Srinivasan, Rekha ; Masood, Daniall ; Slunecka, John L. ; Noldner, Collin J. ; Hanson, Alex D. ; Kruisselbrink, Taylor ; Wang, Xuejun ; Wang, Yiyang ; Yin, Jun ; Rezvani, Khosrow. / UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells. In: Molecular Oncology. 2018 ; Vol. 12, No. 10. pp. 1753-1777.
@article{e65ba8c449e645dc82277896b6885275,
title = "UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells",
abstract = "Overexpression of oncoproteins is a major cause of treatment failure using current chemotherapeutic drugs. Drug-induced degradation of oncoproteins is feasible and can improve clinical outcomes in diverse types of cancers. Mortalin-2 (mot-2) is a dominant oncoprotein in several tumors, including colorectal cancer (CRC). In addition to inactivating the p53 tumor suppressor protein, mot-2 enhances tumor cell invasion and migration. Thus, mot-2 is considered a potential therapeutic target in several cancer types. The current study investigated the biological role of a ubiquitin-like protein called UBXN2A in the regulation of mot-2 turnover. An orthogonal ubiquitin transfer technology followed by immunoprecipitation, in vitro ubiquitination, and Magnetic Beads TUBE2 pull-down experiments revealed that UBXN2A promotes carboxyl terminus of the HSP70-interacting protein (CHIP)-dependent ubiquitination of mot-2. We subsequently showed that UBXN2A increases proteasomal degradation of mot-2. A subcellular compartmentalization experiment revealed that induced UBXN2A decreases the level of mot-2 and its chaperone partner, HSP60. Pharmacological upregulation of UBXN2A using a small molecule, veratridine (VTD), decreases the level of mot-2 in cancer cells. Consistent with the in vitro results, UBXN2A+/− mice exhibited selective elevation of mot-2 in colon tissues. An in vitro Anti-K48 TUBE isolation approach showed that recombinant UBXN2A enhances proteasomal degradation of mot-2 in mouse colon tissues. Finally, we observed enhanced association of CHIP with the UBXN2A-mot-2 complex in tumors in an azoxymethane/dextran sulfate sodium-induced mouse CRC model. The existence of a multiprotein complex containing UBXN2A, CHIP, and mot-2 suggests a synergistic tumor suppressor activity of UBXN2A and CHIP in mot-2-enriched tumors. This finding validates the UBXN2A-CHIP axis as a novel and potential therapeutic target in CRC.",
keywords = "CHIP E3 ligase, UBXN2A, colorectal cancer, mortalin-2, mouse, veratridine",
author = "Sanam Sane and Andre Hafner and Rekha Srinivasan and Daniall Masood and Slunecka, {John L.} and Noldner, {Collin J.} and Hanson, {Alex D.} and Taylor Kruisselbrink and Xuejun Wang and Yiyang Wang and Jun Yin and Khosrow Rezvani",
year = "2018",
month = "10",
doi = "10.1002/1878-0261.12372",
language = "English (US)",
volume = "12",
pages = "1753--1777",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells

AU - Sane, Sanam

AU - Hafner, Andre

AU - Srinivasan, Rekha

AU - Masood, Daniall

AU - Slunecka, John L.

AU - Noldner, Collin J.

AU - Hanson, Alex D.

AU - Kruisselbrink, Taylor

AU - Wang, Xuejun

AU - Wang, Yiyang

AU - Yin, Jun

AU - Rezvani, Khosrow

PY - 2018/10

Y1 - 2018/10

N2 - Overexpression of oncoproteins is a major cause of treatment failure using current chemotherapeutic drugs. Drug-induced degradation of oncoproteins is feasible and can improve clinical outcomes in diverse types of cancers. Mortalin-2 (mot-2) is a dominant oncoprotein in several tumors, including colorectal cancer (CRC). In addition to inactivating the p53 tumor suppressor protein, mot-2 enhances tumor cell invasion and migration. Thus, mot-2 is considered a potential therapeutic target in several cancer types. The current study investigated the biological role of a ubiquitin-like protein called UBXN2A in the regulation of mot-2 turnover. An orthogonal ubiquitin transfer technology followed by immunoprecipitation, in vitro ubiquitination, and Magnetic Beads TUBE2 pull-down experiments revealed that UBXN2A promotes carboxyl terminus of the HSP70-interacting protein (CHIP)-dependent ubiquitination of mot-2. We subsequently showed that UBXN2A increases proteasomal degradation of mot-2. A subcellular compartmentalization experiment revealed that induced UBXN2A decreases the level of mot-2 and its chaperone partner, HSP60. Pharmacological upregulation of UBXN2A using a small molecule, veratridine (VTD), decreases the level of mot-2 in cancer cells. Consistent with the in vitro results, UBXN2A+/− mice exhibited selective elevation of mot-2 in colon tissues. An in vitro Anti-K48 TUBE isolation approach showed that recombinant UBXN2A enhances proteasomal degradation of mot-2 in mouse colon tissues. Finally, we observed enhanced association of CHIP with the UBXN2A-mot-2 complex in tumors in an azoxymethane/dextran sulfate sodium-induced mouse CRC model. The existence of a multiprotein complex containing UBXN2A, CHIP, and mot-2 suggests a synergistic tumor suppressor activity of UBXN2A and CHIP in mot-2-enriched tumors. This finding validates the UBXN2A-CHIP axis as a novel and potential therapeutic target in CRC.

AB - Overexpression of oncoproteins is a major cause of treatment failure using current chemotherapeutic drugs. Drug-induced degradation of oncoproteins is feasible and can improve clinical outcomes in diverse types of cancers. Mortalin-2 (mot-2) is a dominant oncoprotein in several tumors, including colorectal cancer (CRC). In addition to inactivating the p53 tumor suppressor protein, mot-2 enhances tumor cell invasion and migration. Thus, mot-2 is considered a potential therapeutic target in several cancer types. The current study investigated the biological role of a ubiquitin-like protein called UBXN2A in the regulation of mot-2 turnover. An orthogonal ubiquitin transfer technology followed by immunoprecipitation, in vitro ubiquitination, and Magnetic Beads TUBE2 pull-down experiments revealed that UBXN2A promotes carboxyl terminus of the HSP70-interacting protein (CHIP)-dependent ubiquitination of mot-2. We subsequently showed that UBXN2A increases proteasomal degradation of mot-2. A subcellular compartmentalization experiment revealed that induced UBXN2A decreases the level of mot-2 and its chaperone partner, HSP60. Pharmacological upregulation of UBXN2A using a small molecule, veratridine (VTD), decreases the level of mot-2 in cancer cells. Consistent with the in vitro results, UBXN2A+/− mice exhibited selective elevation of mot-2 in colon tissues. An in vitro Anti-K48 TUBE isolation approach showed that recombinant UBXN2A enhances proteasomal degradation of mot-2 in mouse colon tissues. Finally, we observed enhanced association of CHIP with the UBXN2A-mot-2 complex in tumors in an azoxymethane/dextran sulfate sodium-induced mouse CRC model. The existence of a multiprotein complex containing UBXN2A, CHIP, and mot-2 suggests a synergistic tumor suppressor activity of UBXN2A and CHIP in mot-2-enriched tumors. This finding validates the UBXN2A-CHIP axis as a novel and potential therapeutic target in CRC.

KW - CHIP E3 ligase

KW - UBXN2A

KW - colorectal cancer

KW - mortalin-2

KW - mouse

KW - veratridine

UR - http://www.scopus.com/inward/record.url?scp=85052881353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052881353&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12372

DO - 10.1002/1878-0261.12372

M3 - Article

C2 - 30107089

AN - SCOPUS:85052881353

VL - 12

SP - 1753

EP - 1777

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 10

ER -